z-logo
open-access-imgOpen Access
Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells
Author(s) -
Jeanne Galaine,
Guillaume Kellermann,
Yves Claude Guillaume,
Romain Boidot,
Émilie Picard,
Romain Loyon,
Lise Queiroz,
Laura Boullerot,
Laurent Beziaud,
Marine Jary,
Laura Mansi,
Claire André,
Lydie Lethier,
E. Segal,
Christophe Borg,
Yann Godet,
Olivier Adotévi
Publication year - 2016
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.1502633
Subject(s) - internalization , heparan sulfate , telomerase , mhc class ii , microbiology and biotechnology , mhc class i , chemistry , antigen presentation , major histocompatibility complex , biology , biochemistry , cell , cytotoxic t cell , in vitro , gene
Telomerase is a prototype-shared tumor Ag and represents an attractive target for anticancer immunotherapy. We have previously described promiscuous and immunogenic HLA-DR-restricted peptides derived from human telomerase reverse transcriptase (hTERT) and referred as universal cancer peptide (UCP). In nonsmall cell lung cancer, the presence of spontaneous UCP-specific CD4 T cell responses increases the survival of chemotherapy-responding patients. However, the precise mechanisms of hTERT's uptake, processing, and presentation on MHC-II molecules to stimulate CD4 T cells are poorly understood. In this work, by using well-characterized UCP-specific CD4 T cell clones, we showed that hTERT processing and presentation on MHC-II involve both classical endolysosomal and nonclassical cytosolic pathways. Furthermore, to our knowledge, we demonstrated for the first time that hTERT's internalization by dendritic cells requires its interaction with surface heparan sulfate proteoglycans. Altogether, our findings provide a novel mechanism of tumor-specific CD4 T cell activation and will be useful for the development of novel cancer immunotherapies that harness CD4 T cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom